drugset / Trial / NCT05384210

Effect of Milnacipran / Gabapentin in Fibromyalgia

NCT05384210

Unknown 75 enrolled Mansoura University
RandomizedParallel-groupOpen-labelSupportive care

Summary

Gabapentin and milnacipran (MLN) show strong evidence of reduced pain, increased sleep, and improvement in the quality of life in fibromyalgia (FM) patients. Most FM trials focus primarily on pain reduction with monotherapy. Polypharmacy is commonly used, but supportive evidence is limited. The gabapentin-MLN combined therapy may be more effective in female patients with FM than their monotherapy.

Timeline

Start
2022-06
Primary completion
2023-10
Completion
2023-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Gabapentin Small molecule 800 mg
Comparator Milnacipran Other / unclassified 100 mg

Indications